All eyes are on news re Janssen, however as we've previously discussed there are many synergies with other companies that we should all continue to keep our eyes on. Phylogica's PYC35 (Glycinamide) will be launched very soon (as per company Annual Report late 2013/early 2014)....
The potential applications of Glycinamide in the luxury beauty marketplace are substantial, including use in treatments to repair skin following sun or thermal damage and in a rejuvenating serum to reduce skin damage from long-term environmental exposure to UV. This cosmetics deal opens up a new market opportunity for us and could generate meaningful near-term revenue for Phylogica.
The deal with Le Métier is non-exclusive and we are exploring other opportunities to maximise the potential value of the Glycinamide family, particularly as therapeutics. Last month, we teamed up with Bio-Link Australia Pty. Ltd., a specialist life sciences business development company, to assist our efforts to outlicense Glycinamide and the related anti-inflammatory Phylomer peptides for pharmaceutical use.
I have said this before, but I would not underestimate the potential of this Phylomer peptide nor the major patent milestone in the allowance of a US patent application for synthetic Phylomer libraries. The biggie for me will be the universal specificity biosensor. 2014 is shaping up to be an exciting year.
Regards, Tony
PYC Price at posting:
3.2¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)